Why the study?
Does serum alpha-hydroxybutyrate dehydrogenase testing accurately diagnose myocardial infarction compared to existing enzyme tests?
Does serum alpha-hydroxybutyrate dehydrogenase testing accurately diagnose myocardial infarction compared to existing enzyme tests?
The paper introduces serum alpha-hydroxybutyrate dehydrogenase as a potential new diagnostic biomarker for myocardial infarction to overcome the lack of specificity of existing transaminase tests.
Answers are grounded in this paper and cite their sources.
May support alpha-hydroxybutyrate dehydrogenase testing for MI; hypothesis-generating and requires validation before any clinical adoption.
Determination of serum glutamate-oxaloacetate transaminase (S.G.O.T.) activity and serum lactate dehydrogenase (S.L.D.) activity are already well-established procedures in the diagnosis of myocardial infarction. Since S.G.O.T. may be raised in liver disease also, it has become customary to combine its determination with that of serum glutamate-pyruvate transaminase (S.G.P.T.) activity. This latter enzyme, although increased in liver damage, is usually normal or near normal following infarction (Wroblewski and LaDue, 1956).
No takes yet. Share an insight, caveat, or question.
S B Rosalki (1963) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: